EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN THE PLASMA FROM AML PATIENT AND ITS CLINCAL SIGNIFICANCE
- VernacularTitle:急性髓系白血病患者血浆中血管内皮生长因子水平及其临床意义
- Author:
Dan XU
;
Fanyi MENG
;
Zujun JIANG
- Publication Type:Journal Article
- Keywords:
endothelial growth factors;
leukemia, myelocytic, acute;
enzume linked immunosorbent assay
- From:
Medical Journal of Chinese People's Liberation Army
2001;0(09):-
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the role of vascular endothelial growth factor (VEGF) in occurrence and progression of acute myeloid leukemia (AML), enzume linked immunosorbent assay(ELISA) was used for detection of VEGF concentration in plasma from AML patients and normal bone marrow donors.The mean VEGF concentration in the plasma from refractory (558 90pg/ml) and non refractory (392 54pg/ml) AML patients was higher than that from normal donors (57 27pg/ml) and AML patients post Allo BMT (77 31pg/ml).There were significant differences between refractory and non refractory AML group. The baseline VEGF level (196 14pg/ml) of patients in complete remission (CR) after a median follow up of 6 months was significantly lower than that of patients with newly diagnosed or relapsed AML, but significantly higher than that of patients with Allo BMT AML and normal donors. Therefore, abnormal VEGF expession may play an important role in development of AML, and VEGF might be used to evaluate prognosis of AML.
